A Phase 2 interventional study of N-Acetylcysteine (NAC) Treatment in Primary Sclerosing Cholangitis (PSC), sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 40th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 12 of the 21 other live ones, and was the 75th registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 39 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 34 across 94 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,269 studies on the registry; 230 are open to participants now.
Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 6 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC.
The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC.
This is a single-center, open-label study involving approximately 15 adults with PSC. All participants will receive oral NAC at a dose of 1,200 mg per day for the first 12 weeks. At Week 12, the dose will either remain the same or increase to 1,800 mg per day, depending on changes in a liver blood test called alkaline phosphatase (ALP).
Participants will continue treatment through Week 16. Those with a substantial improvement in ALP may be eligible to continue treatment through Week 20.
Researchers will evaluate changes in liver blood tests, treatment safety, side effects, and medication adherence. Additional blood tests may help researchers better understand how NAC affects liver injury.
This study is intended to provide preliminary information about the potential benefits and safety of NAC in PSC. It is not designed to establish whether NAC is an effective treatment for PSC.
This is a prospective, single-center, open-label, single-arm, response-adaptive pilot study designed to assess the biochemical effects, safety, and tolerability of oral N-acetylcysteine (NAC) monotherapy in adults with primary sclerosing cholangitis (PSC).
The study will enroll approximately 15 participants at Brigham and Women's Hospital.
All enrolled participants will receive NAC 600 mg orally twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day. Participants with less than a 40% reduction will increase their total daily dose to 1,800 mg for Weeks 12 through 16.
The primary outcome is the percentage change in serum ALP from baseline to Week 16.
Secondary assessments include changes in ALP at Week 12, biochemical response rates, changes in other liver enzymes (AST, ALT, and GGT), adverse events, treatment tolerability, adherence, and feasibility.
Exploratory assessments will include blood-based biomarkers associated with liver injury and fibrosis, including PRO-C3 and GDF-15.
Study assessments will occur at screening, baseline, and Weeks 4, 8, 12, and 16. Participants who achieve at least a 50% reduction in ALP at Week 16 may be eligible for an optional treatment extension through Week 20, with additional follow-up assessment.
There is no randomization, placebo group, or active comparator. This exploratory study is designed to generate preliminary evidence regarding the biochemical response to NAC monotherapy and inform the design of future controlled clinical trials.
**Inclusion Criteria:**
**Exclusion Criteria:**
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral N-acetylcysteine (NAC) at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in alkaline phosphatase (ALP) of at least 40% from baseline will continue at 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day through Week 16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue treatment through Week 20, according to the study protocol.
Drug: N-Acetylcysteine (NAC) Treatment
N-Acetylcysteine (NAC) will be administered orally at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day for Weeks 12-16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue NAC treatment through Week 20, according to the protocol. The intervention will be administered as oral 600 mg capsules.
Percentage Change in Serum Alkaline Phosphatase (ALP)
Percentage change in serum alkaline phosphatase (ALP) from baseline to Week 16, calculated as \[(Week 16 ALP - baseline ALP) / baseline ALP\] × 100. ALP will be measured using standard clinical laboratory testing. Negative percentage changes indicate a reduction in ALP.
Time frame: Baseline and Week 16
Longitudinal Change in Aspartate Aminotransferase (AST)
Changes in serum AST from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.
Time frame: Baseline, Week 12, and Week 16
Longitudinal Change in Alanine Aminotransferase (ALT)
Changes in serum ALT from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.
Time frame: Baseline, Week 12, and Week 16
Longitudinal Change in Gamma-Glutamyl Transferase (GGT)
Changes in serum GGT from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.
Time frame: Baseline, Week 12, and Week 16
Change in Serum Biomarkers (PRO-C3 and GDF-15)
Changes in serum PRO-C3 and GDF-15 concentrations during NAC treatment, assessed separately as exploratory markers of liver fibrosis and cellular stress.
Time frame: Baseline, Week 8, and Week 16 (PRO-C3); Baseline and Week 16 (GDF-15).
Plan to share: No — There is currently no plan to share individual participant-level data with researchers outside the study team. Study data will be maintained securely in accordance with Mass General Brigham policies and the approved research protocol. Any future data sharing would be subject to applicable institutional and regulatory approvals.
Start is estimated for Dec 2026; primary completion for Jul 2028, 18 months later.
Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetylcysteine
Brigham and Women's Hospital →